Home > Healthcare > Medical Devices > Medical Supplies > specimen collection cards market
Get a free sample of Specimen Collection Cards Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Specimen Collection Cards Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The specimen collection cards industry is consolidated, with key players including Qiagen, PerkinElmer Inc., and others dominating the market. These companies focus on ongoing product innovation, geographical expansion, and partnerships to secure substantial market shares. For instance, in November 2022, PerkinElmer Inc., a global health solutions leader, received FDA authorization to market the EONIS SCID-SMA assay kit for simultaneous detection of SMA and SCID in newborns. This approval expands PerkinElmer's product portfolio, strengthening its competitive edge in the market.
Some of the eminent market participants operating in the specimen collection cards industry include:
Specimen collection cards industry from the cotton & cellulose-based product segment generated USD 230 million in revenue in 2022 and is expected to pick momentum through 2032 owing to the increasing emphasis on sustainability in healthcare practices.
U.S. specimen collection cards industry accounted for USD 161 million in revenue in 2022 and is set to depict steady growth between 2023 and 2032 attributed to the presence of advanced healthcare infrastructure, leadership in medical research, and strict adherence to regulatory standards.
Specimen collection cards industry reached USD 427 million in revenue in 2022 and is anticipated to be worth USD 692 million by 2032 driven by the increasing prevalence of infectious diseases worldwide and the surging demand for diagnostic tools.
Some major specimen collection card companies are Ahlstrom-Munksj